Rocuronium Bromide
Rocuronium bromide is an aminosteroidal, competitive, **non-depolarizing neuromuscular blocking agent (NMBA)**. It is utilized primarily as an adjunct to general anesthesia to facilitate rapid endotracheal intubation and provide profound skeletal muscle relaxation during delicate surgical procedures (e.g., ophthalmic, neurologic, or thoracic surgeries). Key pharmacological characteristics include: * **Rapid to intermediate onset**: Faster onset of action compared to vecuronium or atracurium (2-3 times faster than vecuronium), making it nearly as rapid as succinylcholine but with fewer adverse effects. * **Intermediate duration of action**: Similar duration to vecuronium and atracurium. * **Cardiovascular stability**: Exhibits minimal cardiovascular and histamine-releasing effects compared to older NMBAs. > **Clinical Pearl:** Neuromuscular blocking agents like rocuronium possess **absolutely no analgesic, sedative, or amnestic properties**. Administration to a conscious or inadequately anesthetized patient will result in the terrifying experience of complete paralysis while fully awake and able to feel pain. It must *only* be used in patients who are deeply anesthetized and where mechanical ventilation is immediately available.
Mechanism: Rocuronium acts by competitively antagonizing acetylcholine (ACh) at the neuromuscular junction. * **Mechanism**: It binds to **nicotinic cholinergic receptors** at the motor end plate of skeletal muscle. * **Pathway**: Rocuronium occupies the receptor site โ prevents ACh from binding โ inhibits depolarization of the muscle cell membrane โ results in flaccid paralysis. * **Reversal**: Because the blockade is competitive, it can be antagonized by increasing the concentration of ACh in the synaptic cleft. This is achieved using **acetylcholinesterase inhibitors** (e.g., neostigmine, edrophonium). Alternatively, rocuronium can be directly encapsulated and inactivated in the plasma by the selective relaxant binding agent **sugammadex**.
Dosing by species
- As a neuromuscular blocker ยท 0.6 mg/kg IV ยท IV ยท Single dose ยท Rapid onset, short duration of action, and does not cause significant changes in heart rate.
- Neuromuscular blockade / Endotracheal intubation ยท 0.3-0.6 mg/kg i.v. ยท IV ยท Single dose ยท Approx 20 min at 0.6 mg/kg ยท 0.6 mg/kg has a rapid onset and short duration of action (20 min). Requires prompt successful intubation and ventilation.
- As a neuromuscular blocker ยท 0.6 mg/kg IV ยท IV ยท Single dose ยท Provided predictable blockade without hemodynamic changes, but large variation between individuals; monitoring of neuromuscular block is essential.
- As a neuromuscular blocker ยท 0.5 mg/kg bolus and then a CRI was started immediately at 0.2 mg/kg/hour ยท IV ยท Bolus followed by CRI ยท Authors concluded it was effective and easily applicable, but further work is required on infusion titration.
- Neuromuscular blockade during anaesthesia ยท 0.4 mg/kg i.v. followed, when required, by a maintenance dose of 0.16 mg/kg i.v. prn or continuous rate infusion of 0.2 mg/kg/h ยท IV ยท prn or CRI ยท As needed during surgery ยท Monitoring with a nerve stimulator is recommended.
- Centralize the globe for ophthalmic surgery ยท 0.05-0.1 mg/kg i.v. ยท IV ยท Single dose or prn ยท As needed ยท Considerably lower doses are required for this indication.
Doses are a clinical reference for licensed veterinary professionals. Always confirm against the current label and the individual patient.
Routes of administration
Contraindications
- Hypersensitivity to rocuronium or other neuromuscular blocking agents
- Patients who are not adequately anesthetized or sedated
- Settings lacking immediate access to intubation, mechanical ventilation, and oxygen therapy
- Conscious or inadequately anaesthetized animals
- Lack of positive pressure ventilation facilities
Adverse effects
- Changes in heart rate (mild, transient tachycardia)
- Changes in blood pressure (hypotension or hypertension)
- Severe anaphylaxis (reported in humans)
- Histaminoid reactions (rare)
- Severe burning pain at the injection site (if administered before deep anesthesia is achieved)
- Increased heart rate
- Mild hypertension (at high doses)
Drug interactions
- Other Non-depolarizing Muscle Relaxants ยท May have a synergistic effect if used concurrently with rocuronium.
- Succinylcholine ยท May speed the onset of action and enhance the neuromuscular blocking actions of rocuronium; do not give rocuronium until succinylcholine effects have subsided.
- Aminoglycosides (e.g., gentamicin, amikacin) ยท May enhance or prolong the neuromuscular blocking activity of rocuronium.
- Inhalant Anesthetics (halothane, isoflurane, sevoflurane) ยท May enhance or prolong the neuromuscular blocking activity of rocuronium.
- Clindamycin, Lincomycin ยท May enhance or prolong the neuromuscular blocking activity of rocuronium.
- Dantrolene ยท May enhance or prolong the neuromuscular blocking activity of rocuronium.
- Magnesium Salts ยท May enhance or prolong the neuromuscular blocking activity of rocuronium.
- Piperacillin, Mezlocillin ยท May enhance or prolong the neuromuscular blocking activity of rocuronium.
- Quinidine ยท May enhance or prolong the neuromuscular blocking activity of rocuronium.
- Tetracyclines ยท May enhance or prolong the neuromuscular blocking activity of rocuronium.
- Verapamil ยท May enhance or prolong the neuromuscular blocking activity of rocuronium.
Monitoring
- Degree of neuromuscular blockade (using a peripheral nerve stimulator/Train-of-Four monitor)
- Heart rate and rhythm
- Blood pressure
- Oxygenation (SpO2) and ventilation (End-tidal CO2)
- Depth of anesthesia
- Neuromuscular blockade depth (using a peripheral nerve stimulator)
- Heart rate and blood pressure
- Spontaneous respiratory effort during recovery
Overdose
Overdosage with neuromuscular blocking agents results in **prolonged neuromuscular blockade** (extended paralysis). * **Primary Treatment**: Maintenance of a patent airway, continuous mechanical ventilation, oxygenation, and adequate sedation/anesthesia until full recovery of muscle function is assured. * **Reversal**: Only after spontaneous evidence of recovery is observed should administration of an anticholinesterase drug (e.g., neostigmine) combined with an anticholinergic agent (e.g., atropine or glycopyrrolate to prevent severe bradycardia) be considered. * **Specific Antidote**: Rocuronium's effects can be rapidly and specifically reversed by **sugammadex**, a cyclodextrin binding agent that encapsulates the drug in the plasma.
VetSheet drug reference is intended for licensed veterinary professionals as a clinical decision-support aid, not a substitute for professional judgement or the manufacturerโs current label.